Marksans Pharma Limited
Marksans Pharma is engaged in the Business of Formulation of pharmaceutical products.
What Marksans files
- Others46
- Updates43
- Investor Meet28
- Important12
- Board Meeting12
- PPTs7
Marksans Pharma significantly increased recycled packaging by over 400% and reduced Scope 1 GHG emissions. It plans solar panel installation and wastewater treatment upgrades. However, total GHG emissions (due to Scope 2), SOx emissions, and overall waste increased, while energy efficiency declined. No fines or significant complaints were reported.
Marksans Pharma reports full-year consolidated revenue up 12.5% to ₹2,950.94 Cr, with PAT rising 9.8% to ₹420.06 Cr. EPS grew to ₹9.22. The company established new wholly-owned subsidiaries in Ireland and Canada, granted 400,000 employee stock options, and declared a final dividend of ₹0.90 per share.
Marksans Pharma actively supports corporate integrity and governance, participating in an initiative promoting transparency. The company encourages all stakeholders to uphold ethical standards, reinforcing a commitment to responsible operations.
Marksans Pharma has launched a 100-day campaign for shareholders. Update KYC and claim unclaimed dividends from FY2017-18 onwards to prevent funds from being transferred. Ensure your records are current and secure your entitlements.
Marksans Pharma launched a 100-day campaign encouraging shareholders to claim outstanding dividends from FY2017-18 and update KYC. Act now to prevent your dividends from being transferred out of your reach and ensure proper communication.